Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 292

The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.

Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities

Open access
Ali, K Mahdy, Wonnerth, A, Huber, K, Wojta, J·2012·British Journal of Pharmacology

Abstract

Since the first discovery of an inverse correlation between high‐density lipoprotein‐cholesterol (HDL‐C) levels and coronary heart disease in the 1950s the life cycle of HDL, its role in atherosclerosis and the therapeutic modification of HDL‐C levels have been major research topics. The Framingham study and others that followed could show that HDL‐C is an independent cardiovascular risk factor and that the increase of HDL‐C of only 10 mg·L−1 leads to a risk reduction of 2–3%. While statin therapy and therefore low‐density lipoprotein‐cholesterol (LDL‐C) reduction could lower coronary heart disease considerably; cardiovascular morbidity and mortality still occur in a significant portion of subjects already receiving therapy. Therefore, new strategies and therapies are needed to further reduce the risk. Raising HDL‐C was thought to achieve this goal. However, established drug therapies resulting in substantial HDL‐C increase are scarce and their effect is controversial. Furthermore, it is becoming increasingly evident that HDL particle functionality is at least as important as HDL‐C levels since HDL particles not only promote reverse cholesterol transport from the periphery (mainly macrophages) to the liver but also exert pleiotropic effects on inflammation, haemostasis and apoptosis. This review deals with the biology of HDL particles, the established and future therapeutic options to increase HDL‐C and discusses the results and conclusions of the most important studies published in the last years. Finally, an outlook on future diagnostic tools and therapeutic opportunities regarding coronary artery disease is given.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2012.02081.x

Cites

185 of 185 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 185 references

Cited by

See all 292

Metadata

Authors
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-10-19
Volume
167
Issue
6
Pages
1177-1194
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1535628640
Cited by
292
References
185
FWCI
11.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities. https://app.cochat.ai/papers/10.1111/j.1476-5381.2012.02081.x
The paper
Ali, K. M., Wonnerth, A., Huber, K., & Wojta, J. (2012). Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2012.02081.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.